Automated Accounts Payable provider Glantus Holdings raises 14M and successfully floats on AIM. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Back in April 2011 many close to Futura were touting a similar medical device story to today. 10 years later after Futura got a CE Mark for CSD500. Then all the well known partners handed back the rights to the product including Reckitt, Church and Dwight and Ansell. It has failed to generate any royalties even with many licensing deals with smaller unknown distributors and it didn’t even capture 0.01% of the $4bn global condom market after the company and brokers all forecast it could capture up to 10%.
“If European regulators give CSD500 the green light, it will be because it encourages these men to use protection, and so help to curb the spread of sexually transmitted diseases.
The commercial benefit of this distinction is twofold. Firstly, as Mr. Barder points out, erectile dysfunction is generally found in older men, whereas the inability to maintain an erection while wearing a condom is "much less age specific", meaning a wider potential market.
Moreover, as a medical device rather than a drug, the condoms will be available off the shelf, avoiding the need for a potentially embarrassing trip to the doctor for a prescription.
Reckitt has so far remained quiet about the product, and declined to comment prior to regulatory approval. Reckitt boss Bart Becht has played down the potential of new Durex products, telling analysts back in November: "In terms of SSL innovation, there are some interesting projects in the pipeline, but I would say, most of them are relatively small."
Still, experts say a clinically proven, patented innovation should help the consumer goods firm take market share from major competitors, which include U.S. firm Church & Dwight Co. and Australia's Ansell Ltd.
"If competitors can't come out with a 'me too' in a relatively short period of time—and let's face it, they've known about this as long as anyone else—these clinical claims are going to help Durex's market position," said Chas Manso de Zuniga, a consumer goods analyst at Evolution Securities who has closely followed CSD500's progress under both SSL and Reckitt”
Even go back further to see how long they touted its potential.
“ Market research has shown so far that interest in the condom is enormous, Barder said”
Thanks for your advice, I've done plenty of research which is why your continual posting of irrelevancies and distortions is not going to change anything for me or hopefully anyone else who has done the research and understands exactly how you are distorting and trying to confuse, but you keep going if it pays your bills
DYOR and Go back and read all the old market research on CSD500 that the company claimed would result in CSD500 taking a percentage of the global market after it got it was awarded its CE Mark too. What happens is the expectation from the marketing claims of these Medical device is far from the reality when used in the real world outside the original MDR studies and in market research
“Market research, conducted by an internationally recognised research company, showed that 88% of existing condom users would be interested in purchasing CSD500 and that 49% of non-condom users would be interested in purchasing the product. The research also showed that 46% of men had experienced some loss of sensitivity when using a condom during sexual intercourse, which can lead to loss of erection. This is one reason why some men avoid condoms, thereby increasing the risks of unwanted pregnancies and contracting or spreading sexually transmitted infections”
Yet more regurgitated twisted dishonest deramping from booth masquerading as reasonable debate, it's not even worth bothering with a lengthy rebuttal.
I agree and had MED2005 with an an active GTN drug not failed in the FM57 study and been approved then that would have been a gel that men may use. This MED3000 gel only works due to the physical rubbing and warming (same as using KY warming) and some well described placebo effect from the transdermal application
Also a few years ago. The last time this company was awarded a CE mark Futura was telling shareholders about about all the positive market research on CSD500. “Futura Medical said a majority of men and women who used CSD500 reported longer lasting sexual experience compared to a standard condom, in a company co-sponsored double blind clinical study”. But still Reckitt walked away from it. Then Church & Dwight and then Futura after releasing many RNS about signing many small distribution deals with unknown distributors. It eventually admitted that none of those deals resulted in any royalties and the product was shelved. And remember CSD500 had an active drug component and had at least had undergone double blind studies.
Look too at TPR100. And ask why it too still has not been approved or launched? Remember all transdermal products also have the same placebo effect from “rubbing” any gel.
But least TPR100 had an active component and did not completely fail against its placebo in its studies . Also unlike MED3000 not undergoing a comparison study with KY Warming or Durex play. TPR100 had at least been compared to currently marketed products eg Voltaren and showed non inferiority. Yet still not enough to be approved and launched still.
TPR100, which benefits from the rapid skin permeation rates offered by Futura's proprietary DermaSys® delivery system, demonstrated statistically significant results in a 2015 clinical study comparing the product against both placebo and currently marketed products
Im not a holder but was in the early stages of development, Barder may have got involved with a laugh but now its serious because the gel is about to be issued CE mark in europe.
Ask a guy if he would prefer to put jel on or take a tablet for ed, 7/10 will say gel. Who would want to use viagra and ingest into blood stream when other treatment available now.
I think late may they will get their ce mark. Well done fum..
Good link Inphobe. Now we know that Liambooth is afflicted with such a severe case of poop & scoop that he really ought to get down to the chemist for some Diocalm. (Unless he believes that everything sold in a pharmacy is just a placebo.)
Interesting how some continue to try focus the questioning on me to deflect the questioning away from the company. I am only doing what Futura themselves have told investors to do:
“DISCLAIMER This presentation has been prepared by and is the sole responsibility of the directors of Futura Medical plc (the “Company”). This presentation does not constitute a recommendation regarding the shares of the Company nor a representation that any dealing in those shares is appropriate. The Company accepts no duty of care whatsoever to the reader of this presentation in respect of its contents and the Company is not acting in any fiduciary capacity. The information contained in the presentation has not been verified, nor does this presentation purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in the Company. In all cases potential investors should conduct their own investigations and analysis concerning the risks associated with investing in shares in the Company, the business plans, the financial condition, assets and liabilities and business affairs of the Company, and the contents of this presentation”
Haven't posted here before as I only have a small investment, but the same shenanigans can be seen on other stocks
No telling if it's the case here, but some posters (well, one in particular here) sure fit the bill
Thank god we have the filter function here. The Liam guy is 100% a team.
Been watching Liambooth's pavlovian responses on here with much amusement. I only have a few shares (spare £5K kicking around in last years ISA). It's hilarious. Someone only has to say something mildly positive and away he goes; woof woof woof. Spewing out urls left right and centre. He never has anything informative to say and I must admit my eyes glaze over within a couple of lines and I never click on the URLs. My point in posting is, you can normally get the gist of someone within a few posts. With Liambooth it's like frenetic barking from a dog being fed food it doesn't like and does he really believe anyone reads the urls his team have put together for him?
There are 3 buttons just above the messages share chat , premium share chat and filters , i filtered him from day one , bliss
How do you filter can’t read anymore from Liambooth?
Its been a gravy train for some
Former insurance broker James Barder became involved with Futura having made an investment in what was a private company; pre-Viagra, he, some family and friends all thought it a 'bit of a laugh' initially, but are now very serious. Together they speak for around 25% of the company and many of them came in at the equivalent of 1p a share.
Cash was originally due to run thin by the end of Q1 2021. The, err, unusual deal with 'the Chinese' raised 1.5m (or 2m with exercise of the 22p warrants). Not really enough. But Lombard Odier are holding a lot (10,937,500) of 40p warrants under the terms of the last raise, which comes to just over the 4m if exercised. Which would be convenient.
Dear Liam, you can't just ask random questions implying someone said or implied something then use news links to another product that was not even being discussed.
Well, you can, and you did, but it makes zero sense.
What I said was PET500 was not tested as an ED treatment, so whether it had benefits for ED is unknown.
As for whether MED3000 has performance enhancement benefits is also unknown, as it has not been tested as such.
If you are truly considering investing in this company, you are right to bring up Futura track record of failed partnerships, but your reasons given for such are pretty much speculation.
I'd also say comparing different products to draw what appear to be pretty much random conclusions, doesn't make much sense.
So just for context of anyone reading this thread. PET500 was a performance enhancement product, while MED3000 is a ED product.
While Liam's links do show that ED and premature finishing may not be mutually exclusive, PET500 wasn't designed, tested or marketed as an ED product. As Liam pointed out, the DermaSys used in PET500 was DermaSys Aquafree, which is a type of DermaSys, but is different from the regular types of DermaSys which contain water.
It's worth noting that PET500 (sold as EPIC) is just one of several of these types of spray and is in a crowded market. A quick Google search shows EPIC is still available for sale in USA, even if it isn't listed on the more popular shopping sites.
And all of this has diddly squat to do with MED3000. Let's face it, DermaSys was not expected to have such a positive effect on ED, Futura lucked out. Whether all DermaSys varients would have had the same effect, or it was just the version used in the trial is unknown, as no other varients that I am aware of have been tested and measured under those conditions.
nothing there to suggest lidocaine has any application re ED..completely misleading to reference potential PE treatments containing it.
PET500 which had Dermasys and worked by Evaporative cooing too for the transdermal delivery of lidocaine failed on every aspect.
Interplay Between Premature Ejaculation and Erectile Dysfunction:
Some medications used to treat erectile dysfunction, such as sildenafil (Viagra), tadalafil (Cialis, Adcirca) or vardenafil (Levitra, Staxyn), also might help premature ejaculation.
All wrong based on the FM57 which is the study that Futura are also using to say the placebo Dermasys alone had an effect on ED similar to Med2005 (Dermasys and GTN). Evaporation occurs first in all the products containing Dermasys. So cooling effects occurred in the use of all the products including PET500 but nobody seems to have reported its extra Erectile effects when it was on sale and licensed to Ansell.
“DermaSys® is an enhanced topical drug delivery system containing both volatile (ethanol) and nonvolatile (propylene glycol) solvents and volatile (water) and nonvolatile (glycerol) nonsolvents. Upon application, the volatile solvents evaporate, creating a supersaturated solution of the drug which drives the drug rapidly into tissue”
And same with PET500
PET500 — Futura has an exclusive worldwide agreement with Ansell Limited (“Ansell”), one of the world’s major sexual health companies, for the commercialisation of PET500, our product for enhanced sexual control. PET500 is a topical spray that combines our DermaSys® Aquafree delivery system with a well-known mild topical anaesthetic
also lidocaine is an anesthetic,which iswhy it is used for example in the treatments forED. I'm no scientist, but i assume that an aesthetic response is not going to be conducive to an erectile effect. again more sloppy pseudo scientific "analysis" using agenda and bias as its investigational tools.
So first off, your assumption that the inclusion of DermaSys in the PET500 product would have had the same effect as MED3000 is flawed.
"MED3000 is a unique formulation of DermaSys® using volatile and non-volatile components tailored for the treatment of ED."
Futura refers to DermaSys as a technology as opposed to a single chemical formula, meaning it can likely be tailored to specific uses and has been changed/improved upon over the last seveveral years.
Even if it was a single chemical formula, the addition of the lidocaine (or any other substance) would have changed the chemical properties (like the cooling and warming effects).
Secondly, the "failure" of the PET500 product, was partially to do with poor marketing IMO. Where as MED3000 has already gained interest from leading scientists in the field of ED as well as print and TV media coverage.
very interesting post Discoman.nice to read something different.
Yes, PET500 didnt do very well 7yrs ago. Looks like they are still working on it though.
There are a few products that I can think of that didnt start well, but went on to be a success.
The most obvious is the WD40 spray. So called because it was the 40th version of the Water Displacement test that worked.
Nintendo almost failed until Luigi and Mario came along.
Apple almost went under, Steve Jobs was ousted, but then they came up with Imac and Ipod and it turned the company around.
Dyson made over 5000 prototypes before he found one that worked.
And finally, one that reminds me of the Viagra and MED3000 saga.
Bubble wrap... it was intended to be used as a new trendy wallpaper, but IBM used it as packaging instead and the rest is history
Sometimes failing is the best way to learn.
Yes FUTURA has had its fair share of failures , as do most companies, but I think they have learnt a lot and they will come good in the next 18months. I'm sitting tight.
Liam, two questions about that.
1. What are you on about now?
2. Do you not have anything better to do?
Have a good weekend.